La prevenzione secondaria dell'ictus ischemico: Lo studio sparcl

Translated title of the contribution: Prevention of recurrent stroke

Monia Russo, Alessandra Persico, Piera Tosi, Giuseppe Micieli

Research output: Contribution to journalArticle

Abstract

The importance of the Hypercholesterolemia in the pathogenesis of the cardiovascular pathology and also in the stroke is emphasized through a review of the numerous trials and studies on this topic, (4S: Scandinavian Simvastatin Survival Study; ASCOTT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CARE: Cholesterol And Recurrent Events and, particularly, the study SPARCL: Stroke Preventing Aggressive Reduction in Cholesterol Levels). SPARCL is based on the control of 4731 patients enrolled after a stroke (ischemic or haemorrhagic) or a TIA dated of no more of 6 months. 2365 patients have been randomized to assume 80 mg. diarily of atorvastatine and 2366 a placebo and all must applie the dietetic regime suggested by the american National Cholesterol Education Program. The Authors consider the SPARCL as the better and expose with some tables the details of the research. Those of 4731 pts in whom LDL levels appeared reduced of the 50% (37%) assumed 80 mg. of atorvastatine and the reduction of fatality to 5 years appeared of the 16%.

Original languageItalian
Pages (from-to)55-61
Number of pages7
JournalRivista Italiana di Neurobiologia
Volume4
Issue number1
Publication statusPublished - 2007

Fingerprint

Stroke
Cholesterol
Simvastatin
Dietetics
Hypercholesterolemia
Placebos
Pathology
Lipids
Education
Survival
Research
low density lipoprotein inhibitor

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

La prevenzione secondaria dell'ictus ischemico : Lo studio sparcl. / Russo, Monia; Persico, Alessandra; Tosi, Piera; Micieli, Giuseppe.

In: Rivista Italiana di Neurobiologia, Vol. 4, No. 1, 2007, p. 55-61.

Research output: Contribution to journalArticle

Russo, Monia ; Persico, Alessandra ; Tosi, Piera ; Micieli, Giuseppe. / La prevenzione secondaria dell'ictus ischemico : Lo studio sparcl. In: Rivista Italiana di Neurobiologia. 2007 ; Vol. 4, No. 1. pp. 55-61.
@article{2eb5246c7b764ad1b49559730f255370,
title = "La prevenzione secondaria dell'ictus ischemico: Lo studio sparcl",
abstract = "The importance of the Hypercholesterolemia in the pathogenesis of the cardiovascular pathology and also in the stroke is emphasized through a review of the numerous trials and studies on this topic, (4S: Scandinavian Simvastatin Survival Study; ASCOTT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CARE: Cholesterol And Recurrent Events and, particularly, the study SPARCL: Stroke Preventing Aggressive Reduction in Cholesterol Levels). SPARCL is based on the control of 4731 patients enrolled after a stroke (ischemic or haemorrhagic) or a TIA dated of no more of 6 months. 2365 patients have been randomized to assume 80 mg. diarily of atorvastatine and 2366 a placebo and all must applie the dietetic regime suggested by the american National Cholesterol Education Program. The Authors consider the SPARCL as the better and expose with some tables the details of the research. Those of 4731 pts in whom LDL levels appeared reduced of the 50{\%} (37{\%}) assumed 80 mg. of atorvastatine and the reduction of fatality to 5 years appeared of the 16{\%}.",
keywords = "Cholesterol levels, Statines, Stroke",
author = "Monia Russo and Alessandra Persico and Piera Tosi and Giuseppe Micieli",
year = "2007",
language = "Italian",
volume = "4",
pages = "55--61",
journal = "Rivista Italiana di Neurobiologia",
issn = "0035-6336",
publisher = "Editrice Pisani s.a.s.",
number = "1",

}

TY - JOUR

T1 - La prevenzione secondaria dell'ictus ischemico

T2 - Lo studio sparcl

AU - Russo, Monia

AU - Persico, Alessandra

AU - Tosi, Piera

AU - Micieli, Giuseppe

PY - 2007

Y1 - 2007

N2 - The importance of the Hypercholesterolemia in the pathogenesis of the cardiovascular pathology and also in the stroke is emphasized through a review of the numerous trials and studies on this topic, (4S: Scandinavian Simvastatin Survival Study; ASCOTT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CARE: Cholesterol And Recurrent Events and, particularly, the study SPARCL: Stroke Preventing Aggressive Reduction in Cholesterol Levels). SPARCL is based on the control of 4731 patients enrolled after a stroke (ischemic or haemorrhagic) or a TIA dated of no more of 6 months. 2365 patients have been randomized to assume 80 mg. diarily of atorvastatine and 2366 a placebo and all must applie the dietetic regime suggested by the american National Cholesterol Education Program. The Authors consider the SPARCL as the better and expose with some tables the details of the research. Those of 4731 pts in whom LDL levels appeared reduced of the 50% (37%) assumed 80 mg. of atorvastatine and the reduction of fatality to 5 years appeared of the 16%.

AB - The importance of the Hypercholesterolemia in the pathogenesis of the cardiovascular pathology and also in the stroke is emphasized through a review of the numerous trials and studies on this topic, (4S: Scandinavian Simvastatin Survival Study; ASCOTT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CARE: Cholesterol And Recurrent Events and, particularly, the study SPARCL: Stroke Preventing Aggressive Reduction in Cholesterol Levels). SPARCL is based on the control of 4731 patients enrolled after a stroke (ischemic or haemorrhagic) or a TIA dated of no more of 6 months. 2365 patients have been randomized to assume 80 mg. diarily of atorvastatine and 2366 a placebo and all must applie the dietetic regime suggested by the american National Cholesterol Education Program. The Authors consider the SPARCL as the better and expose with some tables the details of the research. Those of 4731 pts in whom LDL levels appeared reduced of the 50% (37%) assumed 80 mg. of atorvastatine and the reduction of fatality to 5 years appeared of the 16%.

KW - Cholesterol levels

KW - Statines

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=55549111878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549111878&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:55549111878

VL - 4

SP - 55

EP - 61

JO - Rivista Italiana di Neurobiologia

JF - Rivista Italiana di Neurobiologia

SN - 0035-6336

IS - 1

ER -